BACKGROUND: Current ex vivo lung perfusion (EVLP) protocols aim to achieve perfusion flows of 40% of cardiac output or more. We hypothesized that a lower target flow rate during EVLP would improve graft function and decrease inflammation of donation after circulatory death (DCD) lungs. METHODS: A porcine DCD and EVLP model was utilized. Two groups (n = 4 per group) of DCD lungs were randomized to target EVLP flows of 40% (high-flow) or 20% (low-flow) predicted cardiac output based on 100 ml/min/kg. At the completion of 4 hours of normothermic EVLP using Steen solution, left lung transplantation was performed, and lungs were monitored during 4 hours of reperfusion. RESULTS: After transplant, left lung-specific pulmonary vein partial pressure of oxygen was significantly higher in the low-flow group at 3 and 4 hours of reperfusion (3-hour: 496.0 ± 87.7 mm Hg vs. 252.7 ± 166.0 mm Hg, p = 0.017; 4-hour: 429.7 ± 93.6 mm Hg vs. 231.5 ± 178 mm Hg, p = 0.048). Compliance was significantly improved at 1 hour of reperfusion (20.8 ± 9.4 ml/cm H2O vs. 10.2 ± 3.5 ml/cm H2O, p = 0.022) and throughout all subsequent time points in the low-flow group. After reperfusion, lung wet-to-dry weight ratio (7.1 ± 0.7 vs. 8.8 ± 1.1, p = 0.040) and interleukin-1β expression (927 ± 300 pg/ng protein vs. 2,070 ± 874 pg/ng protein, p = 0.048) were significantly reduced in the low-flow group. CONCLUSIONS: EVLP of DCD lungs with low-flow targets of 20% predicted cardiac output improves lung function, reduces edema, and attenuates inflammation after transplant. Therefore, EVLP for lung rehabilitation should use reduced flow rates of 20% predicted cardiac output.
BACKGROUND: Current ex vivo lung perfusion (EVLP) protocols aim to achieve perfusion flows of 40% of cardiac output or more. We hypothesized that a lower target flow rate during EVLP would improve graft function and decrease inflammation of donation after circulatory death (DCD) lungs. METHODS: A porcine DCD and EVLP model was utilized. Two groups (n = 4 per group) of DCD lungs were randomized to target EVLP flows of 40% (high-flow) or 20% (low-flow) predicted cardiac output based on 100 ml/min/kg. At the completion of 4 hours of normothermic EVLP using Steen solution, left lung transplantation was performed, and lungs were monitored during 4 hours of reperfusion. RESULTS: After transplant, left lung-specific pulmonary vein partial pressure of oxygen was significantly higher in the low-flow group at 3 and 4 hours of reperfusion (3-hour: 496.0 ± 87.7 mm Hg vs. 252.7 ± 166.0 mm Hg, p = 0.017; 4-hour: 429.7 ± 93.6 mm Hg vs. 231.5 ± 178 mm Hg, p = 0.048). Compliance was significantly improved at 1 hour of reperfusion (20.8 ± 9.4 ml/cm H2O vs. 10.2 ± 3.5 ml/cm H2O, p = 0.022) and throughout all subsequent time points in the low-flow group. After reperfusion, lung wet-to-dry weight ratio (7.1 ± 0.7 vs. 8.8 ± 1.1, p = 0.040) and interleukin-1β expression (927 ± 300 pg/ng protein vs. 2,070 ± 874 pg/ng protein, p = 0.048) were significantly reduced in the low-flow group. CONCLUSIONS:EVLP of DCD lungs with low-flow targets of 20% predicted cardiac output improves lung function, reduces edema, and attenuates inflammation after transplant. Therefore, EVLP for lung rehabilitation should use reduced flow rates of 20% predicted cardiac output.
Authors: M Valapour; C J Lehr; M A Skeans; J M Smith; K Uccellini; R Lehman; A Robinson; A K Israni; J J Snyder; B L Kasiske Journal: Am J Transplant Date: 2019-02 Impact factor: 8.086
Authors: Matthew J Mulligan; Pablo G Sanchez; Charles F Evans; Yan Wang; Zachary N Kon; Keshava Rajagopal; Aldo T Iacono; James S Gammie; Bartley P Griffith; Si M Pham Journal: J Thorac Cardiovasc Surg Date: 2016-04-28 Impact factor: 5.209
Authors: J Hunter Mehaffey; Eric J Charles; Ashish K Sharma; Dustin T Money; Yunge Zhao; Mark H Stoler; Christine L Lau; Curtis G Tribble; Victor E Laubach; Mark E Roeser; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2016-09-22 Impact factor: 5.209
Authors: Eric J Charles; J Hunter Mehaffey; Ashish K Sharma; Yunge Zhao; Mark H Stoler; James M Isbell; Christine L Lau; Curtis G Tribble; Victor E Laubach; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2017-04-12 Impact factor: 5.209
Authors: Gregor Warnecke; Javier Moradiellos; Igor Tudorache; Christian Kühn; Murat Avsar; Bettina Wiegmann; Wiebke Sommer; Fabio Ius; Claudia Kunze; Jens Gottlieb; Andres Varela; Axel Haverich Journal: Lancet Date: 2012-10-10 Impact factor: 79.321
Authors: Marcelo Cypel; Jonathan C Yeung; Shin Hirayama; Matthew Rubacha; Stefan Fischer; Masaki Anraku; Masaaki Sato; Stephen Harwood; Andrew Pierre; Thomas K Waddell; Marc de Perrot; Mingyao Liu; Shaf Keshavjee Journal: J Heart Lung Transplant Date: 2008-12 Impact factor: 10.247
Authors: Sarah M Haeger; Xinyue Liu; Xiaorui Han; J Brennan McNeil; Kaori Oshima; Sarah A McMurtry; Yimu Yang; Yilan Ouyang; Fuming Zhang; Eva Nozik-Grayck; Rachel L Zemans; Rubin M Tuder; Julie A Bastarache; Robert J Linhardt; Eric P Schmidt Journal: Am J Respir Cell Mol Biol Date: 2018-09 Impact factor: 7.748
Authors: Huy Q Ta; Nicholas R Teman; Irving L Kron; Mark E Roeser; Victor E Laubach Journal: J Thorac Cardiovasc Surg Date: 2022-04-18 Impact factor: 6.439
Authors: Nikhil K Prasad; Chetan Pasrija; Tara Talaie; Alexander S Krupnick; Yunge Zhao; Christine L Lau Journal: Transplantation Date: 2021-05-01 Impact factor: 4.939
Authors: Matthew R Byler; Nathan S Haywood; Dustin T Money; Aimee Zhang; Jared P Beller; Eric J Charles; William Z Chancellor; Huy Q Ta; Mark H Stoler; J Hunter Mehaffey; Victor E Laubach; Irving L Kron; Mark E Roeser Journal: Semin Thorac Cardiovasc Surg Date: 2021-03-11